Aileron Therapeutics
ALRN67
$2.82arrow_drop_down1.55%-$0.04
Penny Stock
ALRN67
$2.82
arrow_drop_down1.55%Performance History
| Key Stats | |
|---|---|
| Open | $2.88 |
| Prev. Close | $2.89 |
| EPS | -3.10 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $65.02M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 2.73 | 3.00 |
| 52 Week Range | 1.01 | 7.42 |
| Ratios | |
|---|---|
| Revenue | - |
| EBITDA Margin % | - |
| EPS | -3.10 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Aileron Therapeutics (ALRN)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Manuel C. Aivado M.D., Ph.D.
- Headquarters
- Boston
- Employees
- 6
- Exchange
- NASDAQ
Keep an eye on Aileron Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Aileron Therapeutics 's (ALRN) price per share?
The current price per share for Aileron Therapeutics (ALRN) is $2.83. The stock has seen a price change of -$0.04 recently, indicating a -1.56% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Aileron Therapeutics (ALRN)?
For Aileron Therapeutics (ALRN), the 52-week high is $7.42, which is 162.65% from the current price. The 52-week low is $1.01, the current price is 179.7% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Aileron Therapeutics (ALRN) a growth stock?
Aileron Therapeutics (ALRN) has shown an average price growth of -6.8% over the past three years. It has received a score of 21 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Aileron Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Aileron Therapeutics (ALRN) stock price performance year to date (YTD)?
As of the latest data, Aileron Therapeutics (ALRN) has a year-to-date price change of -9.46%. Over the past month, the stock has experienced a price change of -20.87%. Over the last three months, the change has been 31.4%. Over the past six months, the figure is -23.44%. Looking at a longer horizon, the five-year price change stands at -67.01%.
help
Is Aileron Therapeutics (ALRN) a profitable company?
Aileron Therapeutics (ALRN) has a net income of -$15.73M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$16.28M. Furthermore, the EBITDA is -$25.4M.
help
What is the market capitalization of Aileron Therapeutics (ALRN)?
Aileron Therapeutics (ALRN) has a market capitalization of $61.1M. The average daily trading volume is 2.85, indicating the stock's liquidity and investor engagement.
News
May 30, 2024
Are Medical Stocks Lagging Sensus Healthcare (SRTS) This Year?
EARNINGS RELEASES AND OPERATING RESULTS
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 7, 2024
Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround
CALENDAR OF EVENTS
HEALTH
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
FINANCING AGREEMENTS
PROSPECTUS/ANNOUNCEMENT OF PROSPECTUS
WARRANTS AND CERTIFICATES
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
FINANCING AGREEMENTS
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million